Invirion Diagnostics, LLC is the first theranostics company
dedicated to the detection, monitoring and treatment of
life-threatening viral diseases such as HIV/AIDS, cervical
cancer, and organ transplant rejection.
Invirion was founded in 1999 with the goal of commercializing
state-of-the-art molecular virology technology to make
a difference in people’s lives. Invirion’s
research, development, and commercialization efforts are
focused on monitoring viruses that cause human disease
and using the information gleaned from these novel assays
to develop therapeutic products that rationally target
the viral lifecycle.
Invirion currently sells viral load monitoring assays
for HIV, the virus that causes AIDS; SIV, the HIV animal
model used in vaccine design; and HPV, the virus associated
with cervical cancer, and HCV, the virus implicated in
cirrhosis and liver cancer. In addition, Invirion is set
to launch an HIV phenotyping assay that cuts the current
assay time and cost by 75% and a pap smear specimen adequacy
test that will reduce the number of repeat visits to the
physician by women with inadequate pap specimens.
• Diagnostic products already on the market
• Proprietary approach to viral diagnostics and
anti-viral drug discovery
• Valuable intellectual property portfolio
• Extensive literature base supporting the utility
of the products
• Collaborations with leading HIV researchers and
clinicians
Invirion developed the paradigm of cellular diagnostics
for viral infections. |
|
|
|
